The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...

The presumptive new CDC director, Dave Weldon, is a known vaccine safety skeptic. In contrast, the FDA choice — Johns Hopkins ...

BridgeBio Pharma Inc. jumped the most in 16 months after its drug got US regulators’ nod to treat a rare, deadly form of ...

Health Recovery Solutions (HRS) is proud to announce a strategic partnership with The Queen's Health Systems to launch a comprehensive Remote Patient Monitoring (RPM) program through the Native ...

CareRx Corporation ("CareRx" or "the Company") today announced that the final tranche of the unsecured convertible debentures (the "Convertible Debentures") originally issued by the Company on ...

On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...

Charles Schwab Investment Management Inc. increased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – ...

PNC Financial Services Group Inc. boosted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 1.2% in ...

The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although, ...

2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, ...